Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403377 | 0.92 | NPC1 (0.43) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL2404525 | 0.90 | NPC1 (0.39) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL3564717 | 0.90 | CA12 (0.46) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL3561925 | 0.90 | KDM4E (0.46) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL3561927 | 0.89 | KDM4E (0.46) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL2402960 | 0.88 | NPC1 (0.44) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL3567356 | 0.88 | NPC1 (0.42) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL3562197 | 0.87 | CA12 (0.41) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL2401632 | 0.85 | RXFP1 (0.36) | PTGS2 | |
| SCHEMBL3559771 | 0.84 | CA12 (0.43) | NPC1RAB9ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012986-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-09-06 | — | — | US | claimed |
| EP-2142527-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-29 | — | — | EP | claimed |
| EP-2142527-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | claimed |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMAN-LA ROCHE, INC. | 2008-11-13 | — | — | US | claimed |
| WO-2008119689-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-8415380-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2011-10-27 | — | — | US | disclosed |
| US-8012986-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2142527-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-29 | — | — | EP | disclosed |
| EP-2142527-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMAN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008119689-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | NPC1 1921/4885RAB9A 1223/4885CA12 4734/4885 |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | NPC1 1921/4885RAB9A 1223/4885CA12 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.